Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Oncology
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Supply Chain
AI and Machine Learning
Awards
Outsourcing Awards
Innovation Awards
AI Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Oncology
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Supply Chain
AI and Machine Learning
Awards
Outsourcing Awards
Innovation Awards
AI Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Pharma
Boehringer Ingelheim divests biologics CDMO unit in China
Blood products developer Raas will pay up to around $3 million to secure a 100% stake in a Boehringer Ingelheim biologics CDMO unit in China.
Fraiser Kansteiner
Sep 24, 2026 11:38am
GSK slammed for grossly misleading, totally unacceptable actions
Sep 24, 2026 11:34am
Clinical trials reach a new automation inflection point
Brought to you by
IQVIA
In landmark for Korean biotech, Elevar wins FDA nod for Lyrfigtu
Sep 24, 2026 11:25am
Advancing mCSPC Treatment: A Closer Look at ADT + Darolutamide with Dr. Rana McKay
Brought to you by
Bayer
Regulatory tracker: AZ continues Breztri's asthma expansion
Sep 24, 2026 10:00am
